ZERO - The Project to End Prostate Cancer
ABOUT PROSTATE CANCERGET INVOLVEDPROGRAMSRESEARCHPARTNERSSTOREABOUT US
Risk Factors
Prevention
Detection
Diagnosis
Treatment
New Prostate Cancer Research
Prostate Cancer Resources
Managing Bone Metastases and Pain
Side Effects of Prostate Cancer Treatment

Prostate Cancer Discovered in 40 Percent of Men Who Test Negative for the Disease

Press Release: Prostate Cancer Foundation of Chicago | 12.15.2008

WESTMONT, Ill., Dec 15, 2008 /PRNewswire via COMTEX/ -- Forty percent of men with prostate cancer may not even know they have it, according to a new research study by the Prostate Cancer Foundation of Chicago. The study revealed the standard office biopsy procedure often isn't enough to properly detect prostate cancer. This new research will be published in an upcoming issue of Urology, a national medical journal.

Researchers used an advanced biopsy technique called stereotactic transperineal prostate biopsy (STPB). This was performed on patients with persistent elevated prostate specific antigen (PSA) levels who previously had at least one negative office biopsy. All patients had received transrectal prostate biopsies (TRPB), administered by a urologist.

"Men who have negative transrectal biopsies and continue to have elevated PSA levels should consider STPB because 40% will harbor malignancy," says Michelle Braccioforte, director of research and education for the Prostate Cancer Foundation of Chicago. "Our level of confidence is greatly enhanced with regards to the presence or absence of cancer, and more specifically, the exact location of the cancer within the prostate."

STPB is performed by taking a median of 40 samples of the prostate through the perineum while the patient is under general anesthesia. Performed as an outpatient procedure, it allows more comprehensive sampling, compared to the transrectal method, which takes fewer samples through the rectum. In addition, by taking more samples during STPB, the exact location of the cancer can be pinpointed.

Between April 2004 and January 2008, 747 patients with high PSA levels were studied. All patients had been tested using TRPB at least once and all results had been negative. All patients received the STPB. Biopsy results identified the presence of cancer in 291 (39%) of the patients.

One in six men in the U.S. will be diagnosed with prostate cancer, the most common form of cancer among men. For those with elevated or rising PSA levels, this is a sign that further testing should be administered to rule out prostate cancer.

The Prostate Cancer Foundation of Chicago, located in Westmont, IL, is a not-for-profit organization that conducts ongoing research intended to improve the diagnosis and treatment of prostate cancer. For more information, visit http://www.chicagoprostatefoundation.org/ to download or call Michelle at 630.654.2515.

Copyright Prostate Cancer Foundation of Chicago 2008

 

All active news articles
About Prostate Cancer  |  Donate  |  Get Involved  |  Programs  |  Research   |  Partners  |  Store  |  About Us  |  Site Map  |  Contact Us  |  Privacy PolicySubscribe to the ZERO Prostate Cancer News Feed  

© Copyright 2010, ZERO - The Project to End Prostate Cancer. All rights reserved.

ZERO does not endorse any course of treatment for men with prostate cancer or other conditions. Treatment decisions should be made by a patient and his health
service provider. If you have problems with the site or need more information, please call us at 1.888.245.9455 or e-mail your comments. All names, logos and articles
are the copyrights of the respective owners.